Neuroscience Development News Today

Bristol Myers Squibb presents new interim pooled long-term safety and metabolic outcome data from the EMERGENT program evaluating KarXT in schizophrenia at the 2024 Annual Meeting of the International...

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

AbbVie Inc on Thursday said Ubrelvy reduces the headache phase of a migraine attack. The North Chicago, Illinois-based pharmaceutical company said Ubrelvy is the first and only acute treatment for...

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

Designation is based on results from the progressive pulmonary fibrosis cohort of the Phase 2 study assessing the safety and efficacy of BMS-986278 treatment versus placebo ...

The FDA has granted Breakthrough Therapy designation to BMS-986278, an investigational LPA1 antagonist, for progressive pulmonary fibrosis.

Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trialSotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any...

New analyses, including late-breaking data and presentations on CAMZYOS® and Eliquis® , reaffirm the companys steadfast dedication to tackling cardiovascular diseases ...

(BPT) - Kim Pfleeger was ready. Clad in gym clothes, she leaned against the wall outside the locker room, eager to return to the basketball court. Her dad, Randy, would

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 24, 2022 /PRNewswire/ -- The Global psychedelic drugs market has been steadily rising for the past few years and is projected